FDA Brief

Warning letters Drugs

FDA warning letter to

Tower Laboratories Ltd.

High riskIssued Dec 23, 2025Posted Jan 6Center for Drug Evaluation and Research (CDER)

FDA warned Tower Laboratories, an OTC drug maker in Montague, MI, for weak out-of-specification investigations and unproven test methods.

What happened

FDA inspected the Tower Laboratories drug manufacturing facility in Montague, Michigan, from July 8 to 11, 2025. Investigators found that failing assay results on stability testing of distributed lots from October 2024 to June 2025 were not thoroughly investigated, no corrective and preventive action (CAPA — the formal fix-and-prevent process) was started, and customers were not told. FDA also found the company had not shown its sample preparation methods for high-performance liquid chromatography testing were suitable, which can produce false failing results.

What FDA found

  1. The company did not thoroughly investigate out-of-specification (OOS — a test result outside the set limit) lab results, and did not find root causes.

    21 CFR 211.192
  2. The company did not start corrective and preventive action (CAPA) after finishing its investigations, a repeat finding from FDA's 2021 inspection.

    21 CFR 211.192
  3. The company did not notify customers that distributed lots failed stability testing at the 9-month timepoint.

    21 CFR 211.192
  4. The company did not show that its sample preparation methods are suitable for testing its drugs, which can lead to inaccurate results.

    21 CFR 211.160(b)
  5. The company did not commit to a retrospective review and risk assessment of all test results produced with these methods, and set no interim controls during revalidation.

    21 CFR 211.160(b)

What FDA wants

FDA tells the company to correct the violations promptly and to reply in writing within 15 working days with an independent retrospective review of invalidated OOS results, remediation plans for its OOS investigation and laboratory systems, and a schedule for any work not finished. FDA may withhold approvals, re-inspect, or take legal action if the problems are not fixed.

Who should pay attention

  • brands and retailers selling OTC drugs made by this contract manufacturer
  • companies buying private-label tablets from Tower Laboratories
  • quality and lab managers who run OOS investigations and method validation

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Bentley Laboratories LLC

    Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.

    High risk
  2. kdc/one Chatsworth, Inc.

    FDA warned kdc/one Chatsworth of CGMP violations in OTC drugs, including missing carcinogen testing and storage temperature failures.

    High risk
  3. ABS Corporation

    ABS Corporation released out-of-specification veterinary drugs and used inadequately tested raw materials, FDA says.

    High risk
  4. Island Kinetics, Inc. d.b.a. CoValence Laboratories

    Island Kinetics (CoValence Laboratories) made OTC acne drugs without process validation and shipped unapproved, misbranded acne products.

    High risk